Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 925 of 994 entries
View as:

Anemia in Patients With a Non-Myeloid Malignancy

Phase: N/A Priority: Normal
NCT ID: NCT00038064 Org: User:
Start: 01/31/02 End: 04/30/04 Due: 04/30/05

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Phase: N/A Priority: Normal
NCT ID: NCT02867813 Org: User:
Start: 09/02/16 End: 03/21/22 Due: 03/21/23

An Open Label Treatment Extension Study of AMG 706

Phase: N/A Priority: Normal
NCT ID: NCT00360867 Org: User:
Start: 12/31/05 End: 07/31/12 Due: 07/31/13

Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire

Phase: N/A Priority: Normal
NCT ID: NCT00121043 Org: User:
Start: - End: - Due: -

Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT05591222 Org: User:
Start: 12/29/22 End: 05/08/25 Due: 05/08/26

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

Phase: N/A Priority: Normal
NCT ID: NCT02222155 Org: User:
Start: 02/04/15 End: 07/19/16 Due: 07/19/17

STAAR-2 Clinical Study

Phase: N/A Priority: Normal
NCT ID: NCT00368901 Org: User:
Start: 01/31/02 End: 05/31/04 Due: 05/31/05

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Phase: N/A Priority: Normal
NCT ID: NCT05540665 Org: User:
Start: 04/26/23 End: 01/04/24 Due: 01/04/25

Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)

Phase: N/A Priority: Normal
NCT ID: NCT00613106 Org: User:
Start: 09/30/07 End: 10/31/08 Due: 10/31/09

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02335983 Org: User:
Start: 04/30/15 End: 10/28/19 Due: 10/28/20

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02147951 Org: User:
Start: - End: - Due: -

A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02520427 Org: User:
Start: 08/31/15 End: 01/09/22 Due: 01/09/23

Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00450216 Org: User:
Start: 03/31/07 End: 10/31/08 Due: 10/31/09

Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis

Phase: N/A Priority: Normal
NCT ID: NCT00980174 Org: User:
Start: 10/01/09 End: 05/23/12 Due: 05/23/13

Treatment for Patients With Osteoarthritis (OA) of the Knee

Phase: N/A Priority: Normal
NCT ID: NCT00110916 Org: User:
Start: 06/30/04 End: 02/28/05 Due: 02/28/06

An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density

Phase: N/A Priority: Normal
NCT ID: NCT01101048 Org: User:
Start: 06/30/10 End: 02/29/12 Due: 02/28/13

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

Phase: N/A Priority: Normal
NCT ID: NCT02729025 Org: User:
Start: 04/14/16 End: 04/05/18 Due: 04/05/19

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02244112 Org: User:
Start: 08/31/14 End: 07/10/19 Due: 07/10/20

Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin

Phase: N/A Priority: Normal
NCT ID: NCT01133522 Org: User:
Start: 06/01/10 End: 09/14/11 Due: 09/14/12

Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study

Phase: N/A Priority: Normal
NCT ID: NCT02792478 Org: User:
Start: 05/06/16 End: 05/31/21 Due: 05/31/22

A Study of CCX168 in Japanese and Caucasian Healthy Adult Males

Phase: N/A Priority: Normal
NCT ID: NCT05988008 Org: User:
Start: 10/23/17 End: 09/20/18 Due: 09/20/19

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Phase: N/A Priority: Normal
NCT ID: NCT01281254 Org: User:
Start: 04/18/11 End: 04/19/17 Due: 04/19/18

Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT00454857 Org: User:
Start: 05/31/06 End: 08/31/08 Due: 08/31/09

Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia

Phase: N/A Priority: Normal
NCT ID: NCT03403374 Org: User:
Start: 08/04/18 End: 11/27/19 Due: 11/27/20

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00005960 Org: User:
Start: 10/31/99 End: - Due: -